Requires health insurance coverage of prescribed anti-obesity medication.
Impact
Should the bill pass, it will significantly affect health insurance policies across New Jersey. By mandating coverage for prescribed anti-obesity medications, the bill could lead to increased accessibility for individuals suffering from obesity, a condition linked to a slew of health issues, including type 2 diabetes and cardiovascular diseases. This could alleviate some financial burdens for patients seeking effective weight management solutions, potentially improving public health outcomes. Insurers will have to adjust their policies to align with the new requirements, impacting how they design benefits and manage premiums.
Summary
Assembly Bill A5200 aims to require health insurance coverage for prescribed anti-obesity medications in the state of New Jersey. The bill mandates that all hospital service corporation contracts, medical service corporation contracts, and health service corporation contracts provide benefits for expenses incurred in obtaining prescription anti-obesity medications, aligning these medications' coverage with other medical conditions treated under such contracts. This legislative move comes in response to the growing prevalence of obesity, which the American Medical Association officially recognized as a disease in 2013, requiring treatment and prevention efforts.
Contention
While A5200 presents a potential boon for public health advocates, it may also face opposition from insurance companies concerned about increased costs and the implications of expanded medication coverage. Critics may argue that mandating such coverage could lead to higher premiums for policyholders as insurers adjust to the increased financial liabilities associated with covering anti-obesity medications. Moreover, discussions around the perceived efficacy and necessity of such medications could evoke debate on whether the state should be involved in expanding coverage for specific medical treatments.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.